Structured Deals Quietly Reshape Venture Capital, One Term Sheet at a Time

When Cascade AI closed its $85 million Series B in late March, the press release listed the lead investor, the post-money valuation, and a gauzy quote about accelerating toward AGI. What the release did not mention was the 2x participating preferred with a 3x cap, the single board seat General Catalyst extracted as a condition of the wire, or the tranched structure that delivered only $35 million of the headline number at close, with the remaining $50 million held behind three separate operational milestones. Four founders I spoke with in the following weeks, all fundraising at the Series A and B stages, described seeing term sheets with similar architecture. None of them were surprised.

The structured deal is not new to venture capital, but its prevalence in 2026 marks a sharp departure from the founder-friendly terms that characterized the 2020-2022 era. Across the market, investors are layering aggressive structural protections into term sheets that the round announcements carefully elide. Participation rights, multiple liquidation preferences, full-ratchet anti-dilution provisions, redemption clauses, and tranched funding structures have all grown more common, according to data tracked by law firms that handle a significant share of venture deal volume. In a year when global venture funding reached a quarterly record of $297 billion, driven by AI mega-rounds for OpenAI, Anthropic, xAI, and Waymo, the headline numbers conceal a more complicated reality at the Series A and B layers, where capital remains disciplined and terms are tightening.

To be clear on the mechanics: a participating preferred stock gives the investor back their money first, $1 per $1 invested, and then converts into common stock to share pro rata in whatever remains. A 2x participating preferred means the investor takes $2 back before conversion. Add a 3x cap and the participation tops out once the investor has received three times their investment. For the Cascade AI deal, the math means General Catalyst recoups its $35 million initial tranche, doubled, off the top of any liquidity event, then shares in the remaining proceeds alongside founders and employees until it hits $105 million in total returns. After that, the participation shuts off and the preferred converts to common. The structure effectively lowers the bar at which the lead investor breaks even, while stretching the exit threshold founders need to clear before seeing meaningful returns.

Why now? The market is bifurcated. At the top end, a small cohort of AI companies can raise eight- and nine-figure rounds on founder-friendly terms because multiple tier-1 funds are competing to lead. Below that tier, the dynamic inverts. Founders who cannot credibly claim to be building the next OpenAI or Anthropic are negotiating from a weaker position, and the investors who sit across the table have spent the 2023-2025 cycle watching their 2021-vintage portfolios struggle to mark up. Those GPs are now demanding equity-like returns with debt-like protections, and the structured deal is the instrument that delivers both. As Rema Matevosyan wrote in Inc., the single capital stack that looked straightforward during the zero-interest-rate period has become a trap for founders who did not understand what they were signing.

What the lead investor gets in a structured round almost never appears in the public announcement. Beyond the liquidation preference, the lead typically negotiates a board seat, sometimes two if the round involves a recapped governance structure. The term sheet frequently includes a pro-rata waiver extracted from earlier investors, meaning the existing seed and Series A funds surrender their right to maintain ownership percentage in the next round, a concession that shifts future upside to the new lead. Blocking rights over debt issuance, M&A, and secondary sales are standard ask items. In some term sheets I have reviewed, the lead also secures a redemption right that allows the investor to force the company to buy back the preferred stock at the original purchase price plus accrued dividends after a set number of years, usually five to seven, turning an equity instrument into something resembling a structured credit product.

These mechanics do not live in isolation. They stack. A Series A that closed with a 1x participating preferred, a Series B that came in with a 2x preference and a 3x cap, and a Series C that adds its own 1.5x preference on top creates a liquidation stack that can easily consume a $400 million exit before a single share of common stock sees a dollar. Founders who raised three structured rounds in sequence sometimes discover, too late, that the exit they spent seven years building will produce nothing for the employees holding options. This is not hypothetical. I have talked with founders who ran the numbers on their own cap tables and found the breakeven point for common had crept above $500 million, higher than any credible acquirer would pay.

I don't care what the post-money says if the structure gives me a 2x liquidation preference and full participation up to a 3x cap. At that point, I'm not betting on the company. I'm betting on the downside protection, and the founder is taking all the binary risk., A general partner at a Bay Area multi-stage fund, speaking on background

Limited partners are paying attention, and they are not unhappy about it. After the 2022-2024 cycle, in which many venture funds marked portfolios aggressively on paper while distribution-to-paid-in ratios languished, LPs began asking sharper questions during annual meetings. Several fund-of-funds analysts I spoke with said they now request anonymized term-sheet summaries as part of their ongoing due diligence on GP relationships. The preference for structured terms is, from the LP perspective, a sign of underwriting discipline: a GP who negotiates a 2x participating preferred in a Series B is signaling that they are not simply betting on the greater fool in the next round. That signal carries weight at a time when fund sizes have ballooned and the spread between top-quartile and median venture returns has widened.

There is, however, a career-risk dimension that goes under-discussed. The partner who leads a structured round with aggressive terms is staking their personal track record on the bet that the company exits above the preference stack. If Cascade AI sells for $300 million, General Catalyst gets its money back with a healthy return, but the founders and the seed investors who backed them at a $12 million post-money valuation get crushed. The lead partner who structured the deal may be made whole on the investment, but the reputational damage with founders and the broader ecosystem accumulates. The best founders talk to each other, and term sheets circulate. A pattern of aggressive structuring follows a partner from deal to deal, and the next hot company may choose a different fund.

The squeeze on common stockholders is where the structured deal's consequences are most acute. Employees who joined early, took below-market salaries, and received option grants priced at the seed round's 409A valuation can find themselves holding equity that is economically worthless even in a mid-nine-figure exit. The liquidation preference stack has to be cleared first, and if it has been built up through successive structured rounds, the waterfall leaves nothing for common. At one enterprise SaaS company that exited last year for $210 million, employees saw zero dollars from their options, according to two former staff members I interviewed. The Series B and C investors had accumulated a combined preference stack that exceeded the sale price.

The next-round implications of a structured deal are equally fraught. When a Series B closes with a 2x participating preferred and a broad-based weighted-average anti-dilution provision, the Series C lead has two options: honor the existing structure, which means writing a larger check to clear the stack and still leave room for common; or negotiate the existing investors down, asking them to convert or waive their preferences as a condition of the new money. Both paths create tension. The first raises the effective cost of the round for the new investor. The second forces an uncomfortable conversation between the Series B lead and the Series C lead, with the founder caught in the middle. In practice, these conversations often result in the earlier investors extracting new concessions, board seats, enhanced information rights, or a sweetened ratchet, in exchange for giving up their preferences.

Firm-level approaches to structured terms vary considerably. General Catalyst and Founders Fund have both deployed structured Series B and C rounds in the last eighteen months, typically with participation rights attached. Andreessen Horowitz has been more selective, reserving aggressive structures for recapitalizations and bridge rounds rather than primary financings, according to three founders who have negotiated with the firm recently. NEA and Khosla Ventures have each used tranched structures, releasing capital in milestones, more frequently than in prior cycles. The law firms that draft these deals, including Cooley, Gunderson, and Fenwick, have seen demand for participation-rights language and ratchet provisions climb steadily since mid-2025, according to partners at two of those firms who declined to be named because they were discussing client matters.

The Fortune Crystal Ball survey of venture capital and private equity trends for 2026 flagged structured deal terms as one of the defining features of the current fundraising environment, noting that GPs who can demonstrate the ability to underwrite downside protection are having an easier time closing their own fundraises. That dynamic creates a self-reinforcing cycle: LPs reward funds that use structured terms, funds deploy those terms into portfolio companies, and the prevalence of participation rights and multiple liquidation preferences becomes more entrenched. The survey quoted one institutional LP who described the shift as a return to the pre-2010 venture playbook, when participating preferred was the norm rather than the exception.

The data on prevalence remains patchy because most term sheets are never made public. Cooley's quarterly venture financing report, which aggregates anonymized deal terms from the firm's own practice, showed that participating preferred stock appeared in 28% of Series B rounds and 34% of Series C rounds in the first quarter of 2026, up from 14% and 19% respectively in the same period two years earlier. Multiple liquidation preferences, defined as anything above 1x, appeared in roughly 11% of Series B deals, a figure that was essentially zero in 2021. These numbers almost certainly understate the true prevalence because firms with the most aggressive terms tend to work with a concentrated set of law firms that do not publicly share their data.

The tension between valuation and structure is the story within the story. A founder who closes a Series B at a $250 million post-money valuation with a 2x participating preferred has sold something closer to a $180 million valuation with cleaner terms, once you factor in the preference overhang. But the headline $250 million number is what the market sees, what the recruiting pitch uses, and what the next round's pricing conversation starts from. This asymmetry between reported valuation and economic reality is corrosive. It inflates expectations among employees who hold options priced off a 409A that is indirectly influenced by the preferred pricing. It sets a baseline for the Series C that the company may not be able to grow into. And it creates a valuation ratchet of its own, distinct from the anti-dilution mechanics in the term sheet.

What happens when a company with a heavily structured cap table tries to raise a down round is the scenario that keeps venture attorneys awake at night. The anti-dilution provisions kick in, adjusting the conversion price of the preferred stock, which in turn increases the number of shares the existing investors receive upon conversion, further diluting the common. The new money demands its own preference, its own board seat, and often a pay-to-play provision that forces existing investors to participate in the round or lose their preferential rights. The cap table can become so encumbered that the company is effectively uninvestable by anyone other than its existing syndicate, a condition that gives the incumbents extraordinary leverage over the founder's next move.

The next twelve months will test whether the structured deal's resurgence is a durable shift or a cyclical peak. Watch for the Q3 2026 venture fundraising data from PitchBook and Preqin, which will show whether LPs continue to reward funds that deploy aggressive structures. Watch the 409A valuations that come out of the major valuation firms, Carta, Aranca, and Scalar, for signs that the preference overhang is being priced into common stock valuations. And watch the exits. A wave of M&A deals where employees walk away with nothing will produce a different kind of founder-investor conversation than the one happening in the boardrooms today. The term sheet is a document that reveals who the investors think will get paid, and in what order, when the music stops. Right now, that order is being rewritten. The press releases just haven't caught up.